ArticleCytotechnology2025
Erianin induces apoptosis of osteosarcoma cells through ferroptosis signaling pathway, and inhibits proliferation and migration of osteosarcoma cells.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting Ferroptosis With Natural Products for the Treatment of Skeletal System Disease: An Updated Review.Journal of cellular and molecular medicine · 2026Review
- THRAP3 promotes ferroptosis resistance in acute myelocytic leukemia through SLU7-mediated alternative splicing of GIT2.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erianin plays a certain role in the treatment of tumors, inflammation, diabetes nephropathy, retinopathy and other diseases. However, the impact and mechanism of Erianin on osteosarcoma (OS) are still unclear. This article aims to investigate the mechanism of action of Erianin in OS. Animal experiments were conducted using nude mice to investigate the in vivo effects of Erianin on OS. Investigations into the in vitro effects of Erianin on OS were conducted through cell experiments utilizing MG-63 and U-2 OS human OS cell lines. Firstly, use the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay to detect cell viability and calculate IC50. Using colony-formation assay to detect the inhibitory effect of Erianin on cell proliferation. Use wound healing assay and cell migration assay to detect the effect of Erianin on the migration of OS cells. Use flow cytometry to detect cell apoptosis. Observe the effect of Erianin on the survival of OS cells under a microscope using Acridine Orange/Propidium Iodide (AO/PI) staining. Use glutathione detection kit to detect the effect of Erianin on the ferroptosis signaling pathway in OS cells. Verify protein expression using western blot. In vitro, Erianin inhibits proliferation and migration of OS cells by regulating apoptotic proteins (Bcl-2, Bax and Cleaved Caspase3), migration proteins(MMP-9, N-cadherin, Vimentin and E-cadherin) and cyclin proteins (CyclinB1 and CDK1), leading to ferroptosis; In vivo, Erianin inhibits tumor growth(Volume inhibition rate: 81.10%, Weight inhibition rate: 53.25%) and causes ferroptosis. The findings of Erianin's induction of apoptosis and ferroptosis, as well as its inhibition of proliferation and migration of OS cells, point to it as a potential therapeutic agent for OS that warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.